FindTrial
Sign In

FT536

DRUG2 trials

Sponsors

Fate Therapeutics, Masonic Cancer Center, University of Minnesota

Conditions

Breast CancerColorectal CancerFallopian Tube CancerGastroEsophageal CancerGynecologic CancerHead and Neck CancerNon Small Cell Lung CancerOvarian Cancer

Phase 1

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
TerminatedNCT05395052
Fate TherapeuticsBreast Cancer, Colorectal Cancer, GastroEsophageal Cancer +4
Start: 2022-05-31End: 2023-08-11Updated: 2023-09-21
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Active, not recruitingNCT06342986
Masonic Cancer Center, University of MinnesotaFallopian Tube Cancer, Gynecologic Cancer, Ovarian Cancer +1
Start: 2024-07-11End: 2027-06-30Updated: 2026-04-02

Related Papers

204 Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity
Regular and Young Investigator Award Abstracts2022-11-013 citations